Kanamycin sulfate pharma Grade

Kanamycin sulfate is an aminoglycoside bacteriocidal antibiotic which acts by binding to the bacterial 30S ribosomes.
It has been well known as desirable antibiotics, which shows an obvious curative effect on serious infections caused by gram-negative bacteria such as Escherichia coil, Klebsiella, Proteus, Pneumonia, Enterobacter aerogenes and Shigella. Clinically, this substance is mainly used for infections caused by sensitive bacteria including pulmonary infection, urinary tract infection, biliary tract infection, sepsis, and abdominal cavity infection. For example, the effective antibacterial activity of kanamycin sulfate has been demonstrated by the treatment of acute gonorrheal urethritis in men, showing that a single parenterally administered dose of 2 mg of kanamycin sulfate cured 144 (93%) of 155 men with acute gonorrheal urethritis.1Moreover, kanamycin sulfate was found to be a valuable drug in the treatment of serious infections in infants and children through an analysis of 140 cases treated during a two-year period.2
Kanamycin was found by Umezawa et al. in the culture broth of Streptomyces kanamyceticus in 1957. It is produced with other components, kanamycins B (bekanamycin) and C, which are also separated during the purification. The compound shows much lower toxicity than the earlier aminoglycosides, streptomycin and neomycin, and strong activity against a wide range of gram-positive and gram-negative bacteria, including Mycobacterium. Kanamycin has been used clinically for treatment of such serious infections as dysentery, salmonellosis, and tuberculosis.
Off-white powder
A broadspectrum antibiotic.